Literature DB >> 18092516

How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach.

Shingo Baba1, Steve Y Cho, Zhaohui Ye, Linzhao Cheng, James M Engles, Richard L Wahl.   

Abstract

To determine the most robust and reproducible parameters for noninvasively estimating tumor cell burden in a murine model, we used real-time in vivo bioluminescent imaging to assess the growth kinetics and dissemination of luciferase-transfected Raji B-cell lymphoma. Bioluminescent signals were acquired every minute for 40 minutes after luciferin injection every other day post-tumor injection. The total 40-minute area under the curve (AUC) of photon intensity (photons/second) was calculated and compared with simplified fixed time point observations (every 5 minutes from 5 to 40 minutes after substrate injection). There was substantial variability in the shape of the time signal intensity curves at different stages of tumor growth in both the intravenous and subcutaneous models. The coefficient of variance in the AUC was 0.27 (intravenous) and 0.36 (subcutaneous) as values determined by fitting the curve, whereas the 20-minute time point measurement varied at 0.29 (intravenous) and 0.37 (subcutaneous). In both the subcutaneous and intravenous models, single time point measurements at 20 minutes had the highest correlation value with AUC. This simplified single time point measurement appears appropriate to estimate the total tumor burden in this model, but the substantial variance at each measurement must be considered in experimental designs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18092516

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   3.250


  16 in total

1.  Subcutaneous administration of D-luciferin is an effective alternative to intraperitoneal injection in bioluminescence imaging of xenograft tumors in nude mice.

Authors:  Ashraf A Khalil; Mark J Jameson; William C Broaddus; Theodore D Chung; Sarah E Golding; Seth M Dever; Elisabeth Rosenberg; Kristoffer Valerie
Journal:  ISRN Mol Imaging       Date:  2013

2.  Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging.

Authors:  Marleen Keyaerts; Carola Heneweer; Lea O Tchouate Gainkam; Vicky Caveliers; Bradley J Beattie; Geert A Martens; Christian Vanhove; Axel Bossuyt; Ronald G Blasberg; Tony Lahoutte
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

3.  Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

Authors:  Niklaus G Schaefer; Engles James; Richard L Wahl
Journal:  Nucl Med Commun       Date:  2011-11       Impact factor: 1.690

4.  Replication Study: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.

Authors:  Mee Rie Sheen; Jennifer L Fields; Brian Northan; Judith Lacoste; Lay-Hong Ang; Steven Fiering
Journal:  Elife       Date:  2019-12-17       Impact factor: 8.140

5.  A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

Authors:  Ralph P Mason; Dawen Zhao; Li Liu; Mary Lynn Trawick; Kevin G Pinney
Journal:  Integr Biol (Camb)       Date:  2011-02-14       Impact factor: 2.192

6.  In Vivo Cellular Imaging for Translational Medical Research.

Authors:  Ali S Arbab; Branislava Janic; Jodi Haller; Edyta Pawelczyk; Wei Liu; Joseph A Frank
Journal:  Curr Med Imaging Rev       Date:  2009-02-01

7.  Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma.

Authors:  Hany A Omar; Aaron M Sargeant; Jing-Ru Weng; Dasheng Wang; Samuel K Kulp; Tushar Patel; Ching-Shih Chen
Journal:  Mol Pharmacol       Date:  2009-08-25       Impact factor: 4.436

8.  Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging.

Authors:  Yusuke Inoue; Shigeru Kiryu; Kiyoko Izawa; Makoto Watanabe; Arinobu Tojo; Kuni Ohtomo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

9.  A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers.

Authors:  Sharon Seiko Hori; Amelie M Lutz; Ramasamy Paulmurugan; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2017-03-10       Impact factor: 12.701

10.  Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission.

Authors:  Marleen Keyaerts; Jacob Verschueren; Tomas J Bos; Lea Olive Tchouate-Gainkam; Cindy Peleman; Karine Breckpot; Chris Vanhove; Vicky Caveliers; Axel Bossuyt; Tony Lahoutte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.